Two Sigma Investments LP Reduces Position in Nkarta, Inc. (NASDAQ:NKTX)

Two Sigma Investments LP decreased its position in Nkarta, Inc. (NASDAQ:NKTX) by 37.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 203,763 shares of the company’s stock after selling 123,221 shares during the period. Two Sigma Investments LP owned 0.29% of Nkarta worth $507,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. Wells Fargo & Company MN increased its position in shares of Nkarta by 27.8% in the 4th quarter. Wells Fargo & Company MN now owns 31,056 shares of the company’s stock valued at $77,000 after acquiring an additional 6,763 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Nkarta by 41.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,958 shares of the company’s stock valued at $60,000 after buying an additional 7,030 shares in the last quarter. American Century Companies Inc. lifted its stake in Nkarta by 8.8% in the 4th quarter. American Century Companies Inc. now owns 90,952 shares of the company’s stock valued at $226,000 after buying an additional 7,378 shares in the last quarter. Wellington Management Group LLP lifted its stake in Nkarta by 4.1% in the 4th quarter. Wellington Management Group LLP now owns 225,224 shares of the company’s stock valued at $561,000 after buying an additional 8,883 shares in the last quarter. Finally, Deutsche Bank AG raised its holdings in Nkarta by 26.1% in the 4th quarter. Deutsche Bank AG now owns 43,157 shares of the company’s stock valued at $107,000 after acquiring an additional 8,946 shares during the last quarter. Hedge funds and other institutional investors own 80.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on NKTX. Needham & Company LLC cut their price target on shares of Nkarta from $11.00 to $10.00 and set a “buy” rating for the company in a report on Thursday, May 15th. William Blair reissued a “market perform” rating on shares of Nkarta in a research report on Thursday, May 15th. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Nkarta in a research report on Thursday, March 27th. Finally, Stifel Nicolaus decreased their price objective on shares of Nkarta from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, March 27th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Nkarta presently has an average rating of “Buy” and a consensus target price of $14.67.

Nkarta Price Performance

Shares of NKTX stock opened at $1.87 on Tuesday. The firm has a market cap of $132.69 million, a P/E ratio of -0.99 and a beta of 0.72. Nkarta, Inc. has a 1-year low of $1.31 and a 1-year high of $8.23. The firm has a fifty day moving average of $1.82 and a two-hundred day moving average of $2.07.

Nkarta (NASDAQ:NKTX) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.01. On average, sell-side analysts expect that Nkarta, Inc. will post -1.7 EPS for the current year.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.